Collegium is executing a strategic pivot into ADHD therapies, evidenced by 41% ADHD product growth and the $655.4M AZSTARYS acquisition, which drove revenue to $199.9M in 2026Q2. However, this transformation has compressed gross margins to 55.2% and operating ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $1.92+11.6% vs $1.72 | $200M+0.1% vs $200M |
Q2 2026 May 7, 2026 | $1.76+15.8% vs $1.52 | $194M+4.9% vs $184M |
Q1 2026 Feb 26, 2026 | $2.04-4.7% vs $2.14 | $205M-0.4% vs $206M |
Q4 2025 Nov 6, 2025 | $2.25+21.0% vs $1.86 | $209M+1.6% vs $206M |
Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that its management will participate in the following investor conferences:
Freestone Grove Partners LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 44,493 shares of the specialty pharmaceutical company's stock, valued at approximately $1,611,000. Freestone Grove Partners LP owned
BlackRock Inc. bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,441,202 shares of the specialty pharmaceutical company's stock, valued at approximately $196,972,000. BlackRock Inc. owned about 16.78% of Collegium
Benchmark COLL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Collegium Pharmaceutical, Inc. (COLL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.45 | $728.14M | 12.98 | 23.62% | 8.05% | 23.7% | — | |
| $21.64 | $2.1B | -42.43 | 504.79% | -0.11% | -0.33% | — | |
| $40.48 | $2.34B | 14.94 | 21.51% | 18.88% | 20.06% | — | |
| $43.39 | $2.52B | -63.81 | 8.63% | -13.23% | -10.42% | — | |
| $24.63 | $968.82M | 153.94 | 3.63% | 1.96% | 2.13% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — |
Collegium Pharmaceutical, Inc. (COLL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Collegium Pharmaceutical, Inc. (COLL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 6, 2026·SEC
May 15, 2026·SEC
Get notified when COLL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Collegium Pharmaceutical, Inc. (COLL) stock FAQ — growth, dividends, profitability & financials explained
Collegium Pharmaceutical, Inc. (COLL) reported $808.2M in revenue for fiscal year 2025.
Collegium Pharmaceutical, Inc. (COLL) grew revenue by 23.6% over the past year. This is strong growth.
Yes, Collegium Pharmaceutical, Inc. (COLL) is profitable, generating $47.9M in net income for fiscal year 2025 (8.1% net margin).
Collegium Pharmaceutical, Inc. (COLL) has a return on equity (ROE) of 23.7%. This is excellent, indicating efficient use of shareholder capital.
Collegium Pharmaceutical, Inc. (COLL) generated $328.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
